Abzena operates in the biopharmaceutical sector, providing proprietary technologies and complementary solutions for the development of biopharmaceutical products. The company serves a diverse range of clients, including clinical-stage biopharmaceutical companies and organizations involved in the development of innovative biologic drugs. Abzena's market includes the global biopharmaceutical industry, focusing on areas such as antibody drug conjugates, cell line development, and bioconjugation.

Abzena's business model revolves around offering specialized services and technologies that facilitate the development and manufacturing of biopharmaceutical products. The company generates revenue through service contracts and partnerships with biopharmaceutical companies, providing expertise in areas like mammalian manufacturing, cell banking, process development, and analytical development.

Key clients include companies like Sonnet BioTherapeutics and Immunome, who have selected Abzena for their manufacturing and development needs. Abzena's comprehensive service offerings enable its clients to advance their biopharmaceutical products from research and development stages to clinical trials and beyond.

Keywords: biopharmaceutical, antibody drug conjugates, cell line development, bioconjugation, mammalian manufacturing, process development, analytical development, clinical-stage, proprietary technologies, biopharmaceutical products.